Cancer name Pancreatic Cancer
Cancer Type PAAD
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment Verticillin A
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature PD-L1
Official Symbol PDCD1
Mode of action TRAN_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description Interestingly, verticillin A statistically significantly decreased the H3K4me3 levelin thecd274promoter region in a dose-dependent manner inpancreatic tumor cells in vitro (P< .02) . Consistentwith the decreased H3K4me3 levels in thecd274promoter re-gion, verticillin A dramatically decreased the PD-L1 mRNA level(P?.01) (Figure 4B) and the protein level (P<.007) inthe tumor cells in vitro. Treatment of tumor-bearing mice withverticillin A also decreased the H3K4me3 level in thecd274promoter region in the orthotopic tumor tissues (P<.04). PD-L1 mRNA level (P<.02) and proteinlevel (P<.001) were also statistically significantly decreased in the orthotopic tumor tissues in vivo.
PMID 28131992
Title The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion